Adenosine deaminase impairment and ribonucleotide reductase in human cells.
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology; D000243:Adenosine Deaminase / Q000172:deficiency*; D058892:Adenosine Deaminase Inhibitors; D002455:Cell Division / Q000187:drug effects; D003839:Deoxyadenosines / Q000494:pharmacology; D006367:HeLa Cells / Q000166:cytology / Q000201:enzymology*; D006801:Humans; D007399:Interphase / Q000187:drug effects; D009700:Nucleoside Deaminases / Q000172:deficiency*; D012264:Ribonucleotide Reductases / Q000378:metabolism*; D013942:Thymine Nucleotides / Q000378:metabolism
D058892:Adenosine Deaminase Inhibitors; D003839:Deoxyadenosines; D013942:Thymine Nucleotides; C010192:9-(2-hydroxy-3-nonyl)adenine; D012264:Ribonucleotide Reductases; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase; D000225:Adenine; D000241:Adenosine; C024157:thymidine 5'-triphosphate